YXgene’s Post

"Exciting new research highlights the identification of immune-related gene signatures for predicting prognosis in cholangiocarcinoma patients. This study exemplifies how integrating immunology and cancer research can drive personalized treatment strategies. If this approach piques your interest, reach out! 🚀 #CancerResearch #Bioinformatics #Cholangiocarcinoma #PrognosticModels #Immunology"

A new study has found an interesting link between gene mutations in blood #cancer and #arthritis. The publication explains how specific gene mutations in blood cancer can impact autoimmune diseases such as seronegative RA. The study suggests that effective metabolic therapies in treating blood cancer may help arthritis patients.   → Conclusion: • IDH mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis. • High levels of 2-hydroxyglutarate mediate IDH-associated activation of innate immune response.   → Lih En Hong, Mihir D Wechalekar, and Devendra Hiwase led the research team at the Royal Adelaide Hospital in Australia for this study.    → Publication: Hong, Lih En, et al. "IDH Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation." Blood (2024).   📖 Read on…https://lnkd.in/egV5am-P   #Inflammation #Immunotherapy #DrugDevelopment

🔬✨ New Protocol Alert! Protocol to establish an accelerated murine model for Helicobacter-induced gastric cancer by Bali et al. from Marygorret Obonyo’s lab from UC San Diego   Summary: Learn how to establish an accelerated murine model for Helicobacter-induced gastric cancer, featuring rapid disease progression with precancerous lesions developing within 6 months post-infection. Protocol Highlights: Explore the accelerated model for Helicobacter-induced gastric cancer, covering infection procedures, disease severity assessment, and gene expression analysis techniques for studying disease progression. Read the full protocol here: https://lnkd.in/e2gn5xkD #STARProtocols #GastricCancerModel #HelicobacterInfection #ResearchMethods #Protocols #CellPress

Looking for an advanced human in vitro liver model for your research? Check out our poster on "A comprehensive and scalable human liver-on-chip model for fibrosis drug discovery and gene delivery applications." MIMETAS's advanced 3D liver model mimics steatosis and fibrosis using multiple cell types (hepatocytes, endothelial, stellate, and immune cells), offering a powerful tool for studying liver health and disease. Compatible with automation and high-throughput screening, it’s paving the way for breakthroughs in therapies for liver diseases and cancer. 🔗 Download the poster now to learn more: https://lnkd.in/eanzwqam #LiverOnChip #FibrosisResearch #GeneDelivery #DrugDiscovery

Supporting Immune System Health: The Potential of Clenoptele and Clinoptilolite Learn how the Cliniptilolte inhibits viral replication and examine its potential role in supporting immune system health. Explore the activation of the p-tumor suppressor gene and its impact on cancer cells. Discover the potential benefits of zeolites in health. #SupportingImmuneSystem #ClenopteleBenefits #ClinoptiloliteStudies #PTumorSuppressorGene #ZeolitesInHealth #ViralReplicationInhibition #CancerResearch #ImmuneHealth #HealthBenefits #NaturalRemedies

🌟 The article, titled "Relationship between vaginal and oral microbiome in patients of human papillomavirus (HPV) infection and cervical cancer", was published in Journal of Translational Medicine. The aim of this study was to assess the microbial variations and biomarkers in the vaginal and oral environments of patients with human papillomavirus (HPV) and cervical cancer (CC) and to develop novel prediction models. 🔍 Microbiota analysis was conducted using full-length 16S rDNA gene sequencing with the PacBio platform. HPV infection and CC impact both the vaginal and oral microenvironments, affecting systemic metabolism and the synergy between bacteria. This suggests that the use of oral flora markers is a potential screening tool for the diagnosis of CC. 🔬 #BMKGENE provided sequencing and analysis services of full-length 16S rDNA gene for this study. #FullLength16S #Microbiome #HumanPapillomavirus #CervicalCancer

https://lnkd.in/efj_w3vQ Nice explanation from our Grant Partner, Hartford HealthCare's Niamey Wilson, MD, FACS on the BRCA gene and genetic testing. You can view an additional discussion on this topic on our PinkAid YouTube channel. #pinkaid #hartfordhealthcare #breastcancer #breastcancerrisk #BRCA #genetictesting #breastcancerscreening

Did you know that our breast and gyne cancer gene test goes beyond BRCA testing? In fact, our test covers these: ✅ ATM ✅ BARD1 ✅ BRCA1 ✅ BRCA2 ✅ BRIP1 ✅ CHEK22 ✅ EPCAM ✅ MLH1 ✅ MSH2 ✅ MSH6 ✅ PALB2 ✅ PTEN ✅ RAD51C ✅ RAD51D ✅ STK11 ✅ TP53 To support 💗 Breast Cancer Awareness Month💗, we have knocked £50 off our test, making it just £449 for the whole of October. Why choose our test? ● Fast: results in 20 working days ● Simple: saliva test at home ● NHS recognised ● Quality: testing, analysis and interpretation by UKAS-accredited ISO15189 Genomics Laboratory Service ● Pre and post genetic counselling included via GCRB-registered Genetic Counsellors Knowledge is power Visit our website to learn more and grab our offer before the end of October: https://lnkd.in/epcX_id3 PS: Don't forget that breast cancer can impact ♂️ men and ♀️ women. #BRCA #hereditarycancer #genetics #cancergene #breastcancerawarenessmonth #knowledgeispower

Gene&Cell Therapy >> Seven patients diagnosed with blood cancer after Skysona treatment, new data show: Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood cancer months or years after treatment, according to data published on Wednesday in the New England Journal of Medicine. Researchers have long known that therapies developed with lentiviral vectors could, in some cases, cause cancer, but they have been seeking to understand why Skysona comes with a seemingly greater risk. The cases may relate to the design of the lentiviral vector used in the treatment, scientists hypothesize. Bluebird’s eli-cel was approved in 2022 under the brand name Skysona to treat cerebral adrenoleukodystrophy, also known as CALD. The condition mostly affects young boys and progresses rapidly without treatment, leading to neurological decline or death. Skysona was approved in 2022 with a black box warning for hematologic malignancy, and the FDA updated its label in April to disclose that there had been six cases of the cancer out of 67 patients dosed in clinical studies. An additional case has been diagnosed since then, according to new data published in NEJM. The patients received Skysona when they were between 5 and 13 years old, with the cancer diagnoses occurring 14 to 92 months later, according to the data. In an editorial published alongside the data, Cynthia Dunbar, a hematologist at the NIH’s National Heart, Lung and Blood Institute, wrote that more cases may appear over time. “Unfortunately, I think she’s right,” Christine Duncan, lead author of the NEJM study and Boston Children’s Hospital senior physician, told Endpoints News. “Patients are being followed very closely. The families are being very educated. They all know about all of these cases.” Duncan and her team hypothesized that the cases may have been driven by the design of the lentiviral vector used in Skysona. CALD is caused by a mutation in a gene called ABCD1. Skysona works by using a lentivirus to insert a functioning form of the ABCD1 gene. Skysona’s lentiviral vector was designed with the use of a viral promoter, intended to help drive strong expression of the gene. But a risk of that type of promoter is oncogenesis, or driving the development of cancer, Duncan explained. “We’re relatively confident that that promoter in the design of the vector is driving this,” she said. “The question then is, in my mind, is it driving it alone, or are there other factors that contribute?” Duncan noted that patients in one study, ALD-102, which has reported only one case of hematologic cancer, received a stronger chemotherapy regimen as part of preparation for treatment than another study, ALD-104, which reported the other six cases. But at this time, it remains unclear whether that made a difference, or… #lucidquest #genetherapy #celltherapy

A new study finds precancerous colon cells turn on a gene called SOX17, which helps them evade detection and develop into more advanced tumors. | Click below to read the full article on Sunalei